Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2023-09-29 eCollection Date: 2023-06-01 DOI:10.2217/hep-2023-0006

Yajing Wang, Zhanqi Wei, Zheng Zhang, Jingyi Xu, Yaqin Wang, Qian Chen, Yuewei Zhang

{"title":"Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.","authors":"Yajing Wang, Zhanqi Wei, Zheng Zhang, Jingyi Xu, Yaqin Wang, Qian Chen, Yuewei Zhang","doi":"10.2217/hep-2023-0006","DOIUrl":null,"url":null,"abstract":"Aim: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma.Patients & methods: Retrospective analysis of patients receiving FOLFOX-HAIC with or without lenvatinib.Results: Forty-one patients were included, with 22 patients receiving HAIC alone and 19 patients receiving HAIC plus lenvatinib. Combination treatment significantly prolonged overall survival and progression-free survival compared with HAIC alone. Grade 1-2 adverse events were more frequent in the combination group but manageable. No severe AEs or treatment-related deaths were reported.Conclusion: FOLFOX-HAIC plus lenvatinib has the potential to be a treatment option for unresectable cholangiocarcinoma.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/57/hep-10-49.PMC10577516.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2023-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma.

Patients & methods: Retrospective analysis of patients receiving FOLFOX-HAIC with or without lenvatinib.

Results: Forty-one patients were included, with 22 patients receiving HAIC alone and 19 patients receiving HAIC plus lenvatinib. Combination treatment significantly prolonged overall survival and progression-free survival compared with HAIC alone. Grade 1-2 adverse events were more frequent in the combination group but manageable. No severe AEs or treatment-related deaths were reported.

Conclusion: FOLFOX-HAIC plus lenvatinib has the potential to be a treatment option for unresectable cholangiocarcinoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝动脉灌注化疗加或不加乐伐替尼治疗不可切除胆管癌：一项单中心回顾性研究。

目的：本研究的目的是比较奥沙利铂、氟尿嘧啶和亚叶酸（FOLFOX）联合乐伐替尼和单独使用FOLFOX-HAIC的肝动脉灌注化疗（HAIC）对不可切除胆管癌患者的疗效和安全性。患者和方法：对接受FOLFOX HAIC治疗的患者进行回顾性分析，无论是否使用乐伐替尼。结果：纳入41名患者，其中22名患者单独接受HAIC治疗，19名患者接受HAIC加乐伐替尼治疗。与单独使用HAIC相比，联合治疗显著延长了总生存期和无进展生存期。1-2级不良事件在联合用药组中更为常见，但可控制。无严重AE或治疗相关死亡报告。结论：FOLFOX-HAIC联合乐伐替尼有可能成为不可切除胆管癌的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.